1. Home
  2. DVAX vs ORC Comparison

DVAX vs ORC Comparison

Compare DVAX & ORC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DVAX
  • ORC
  • Stock Information
  • Founded
  • DVAX 1996
  • ORC 2010
  • Country
  • DVAX United States
  • ORC United States
  • Employees
  • DVAX N/A
  • ORC N/A
  • Industry
  • DVAX Biotechnology: Pharmaceutical Preparations
  • ORC Real Estate Investment Trusts
  • Sector
  • DVAX Health Care
  • ORC Real Estate
  • Exchange
  • DVAX Nasdaq
  • ORC Nasdaq
  • Market Cap
  • DVAX 1.2B
  • ORC 1.0B
  • IPO Year
  • DVAX 2004
  • ORC 2013
  • Fundamental
  • Price
  • DVAX $10.44
  • ORC $7.65
  • Analyst Decision
  • DVAX Buy
  • ORC Hold
  • Analyst Count
  • DVAX 4
  • ORC 2
  • Target Price
  • DVAX $26.50
  • ORC N/A
  • AVG Volume (30 Days)
  • DVAX 1.3M
  • ORC 5.3M
  • Earning Date
  • DVAX 11-05-2025
  • ORC 10-23-2025
  • Dividend Yield
  • DVAX N/A
  • ORC 18.85%
  • EPS Growth
  • DVAX N/A
  • ORC N/A
  • EPS
  • DVAX N/A
  • ORC 0.57
  • Revenue
  • DVAX $316,268,000.00
  • ORC $80,187,000.00
  • Revenue This Year
  • DVAX $23.23
  • ORC $75.23
  • Revenue Next Year
  • DVAX $16.57
  • ORC $53.72
  • P/E Ratio
  • DVAX N/A
  • ORC $13.35
  • Revenue Growth
  • DVAX 26.66
  • ORC 5.93
  • 52 Week Low
  • DVAX $9.20
  • ORC $5.69
  • 52 Week High
  • DVAX $14.63
  • ORC $9.01
  • Technical
  • Relative Strength Index (RSI)
  • DVAX 58.99
  • ORC 70.55
  • Support Level
  • DVAX $10.03
  • ORC $7.40
  • Resistance Level
  • DVAX $10.59
  • ORC $7.78
  • Average True Range (ATR)
  • DVAX 0.22
  • ORC 0.13
  • MACD
  • DVAX 0.06
  • ORC 0.04
  • Stochastic Oscillator
  • DVAX 81.25
  • ORC 81.94

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

About ORC Orchid Island Capital Inc.

Orchid Island Capital Inc is a specialty finance company that invests in residential mortgage-backed securities. The principal and interest payments of its RMBS are guaranteed by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, or the Government National Mortgage Association, and are backed by single-family residential mortgage loans. The company's investment portfolio is divided into two categories namely traditional pass-through Agency RMBS; and structured Agency RMBS, such as collateralized mortgage obligations, interest-only securities, inverse interest-only securities, and principal-only securities, among other types of structured Agency RMBS.

Share on Social Networks: